Business Context and Reporting Period
This Form 8-K filing by Becton, Dickinson and Company (BD) was submitted on August 22, 2022, with the earliest event reported on that date. The report focuses on significant executive leadership changes within the company's Medical and Interventional segments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and personnel changes rather than a financial results announcement.
Material Changes
The primary material change reported is the restructuring of senior leadership roles effective September 2022:
- Departure: Simon Campion, Executive Vice President and President of the Medical Segment, will depart BD on September 9, 2022, to pursue an executive role in the health care industry.
- Appointments: Michael Garrison has been appointed Executive Vice President and President of the Medical Segment, and Richard Byrd has been appointed Executive Vice President and President of the Interventional Segment. Both appointments are effective September 6, 2022.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or specific risk factors. It references a press release issued on August 25, 2022, regarding these personnel changes, which is attached as Exhibit 99.1. The filing explicitly states that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the effective dates of the new segment presidents (September 6, 2022) and the departure of Simon Campion (September 9, 2022).
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition strategy.
- Confirm that no financial performance metrics were updated in this specific filing.